Results 261 to 270 of about 614,006 (307)
Dual targeting of CD155 augments the antitumor efficacy of ROR1-CAR-T cells in ovarian cancer. [PDF]
Cancer Immunol ImmunotherYe Y +6 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Neurosurgery Clinics of North America, 2021
Chimeric antigen receptor T (CAR-T) cells, an immunotherapy that demonstrates marked success in treatment of hematologic malignancies, are an emergent therapeutic for patients with glioblastoma (GBM). GBM CAR-T trials have focused on targeting well-characterized antigens in the pathogenesis of GBM.
Thilan, Tudor +2 more
openaire +2 more sources
Chimeric antigen receptor T (CAR-T) cells, an immunotherapy that demonstrates marked success in treatment of hematologic malignancies, are an emergent therapeutic for patients with glioblastoma (GBM). GBM CAR-T trials have focused on targeting well-characterized antigens in the pathogenesis of GBM.
Thilan, Tudor +2 more
openaire +2 more sources
2020
In 1891, Dr. William B. Coley, an American surgeon, made a compelling observation that immune system can be triggered to shrink tumors. The quest to exploit the power of immunotherapy however was forestalled by an era of chemotherapy that ensued.
Ranjit, Nair, Jason, Westin
openaire +3 more sources
In 1891, Dr. William B. Coley, an American surgeon, made a compelling observation that immune system can be triggered to shrink tumors. The quest to exploit the power of immunotherapy however was forestalled by an era of chemotherapy that ensued.
Ranjit, Nair, Jason, Westin
openaire +3 more sources
New England Journal of Medicine, 2017
More than 7 years have passed since the regression of advanced lymphoma was first reported in a patient who had undergone the infusion of T cells engineered to express a chimeric antigen receptor (CAR) targeting the CD19 antigen expressed on the surface of both normal and malignant B cells.1 Subsequent trials of CD19-targeted CAR T-cell therapy showed ...
Eric, Tran, Dan L, Longo, Walter J, Urba
openaire +2 more sources
More than 7 years have passed since the regression of advanced lymphoma was first reported in a patient who had undergone the infusion of T cells engineered to express a chimeric antigen receptor (CAR) targeting the CD19 antigen expressed on the surface of both normal and malignant B cells.1 Subsequent trials of CD19-targeted CAR T-cell therapy showed ...
Eric, Tran, Dan L, Longo, Walter J, Urba
openaire +2 more sources
2022
Adaptive immunotherapy has been growing as a therapeutic alternative for cancer and other diseases treatment; chimeric antigen receptor (CAR) T cells comprise a type of adaptive immunotherapy, with recombinant receptor constructs expressed in T cells to target cells expressing specific antigens, is a potential new treatment for blood cancers and solid ...
openaire +2 more sources
Adaptive immunotherapy has been growing as a therapeutic alternative for cancer and other diseases treatment; chimeric antigen receptor (CAR) T cells comprise a type of adaptive immunotherapy, with recombinant receptor constructs expressed in T cells to target cells expressing specific antigens, is a potential new treatment for blood cancers and solid ...
openaire +2 more sources
Nature Biomedical Engineering, 2020
Locally delivering therapeutic T cells into solid tumours in mice via thin nitinol films loaded with the cells lengthens the animals’ survival.
Kwasi Adu-Berchie, David J. Mooney
openaire +2 more sources
Locally delivering therapeutic T cells into solid tumours in mice via thin nitinol films loaded with the cells lengthens the animals’ survival.
Kwasi Adu-Berchie, David J. Mooney
openaire +2 more sources
Potency monitoring of CAR T cells
2023The effector potency of chimeric antigen receptor (CAR) T cell therapeutic products is essential to their clinical antitumor responses, and potency monitoring is a critical quality control method for CAR T cell therapy platforms. While many in vitro assays enable high-throughput assessment of CAR T cell cytotoxicity, it has been challenging for these ...
Dongrui, Wang +4 more
openaire +2 more sources
CAR-T cells: the Chinese experience
Expert Opinion on Biological Therapy, 2020Chimeric antigen receptor T (CAR-T) cells are harnessed to identify and lyse malignant cells specifically, efficiently, and independently of the major histocompatibility complex (MHC). As a result, prognoses of relapsed or refractory (R/R) B cell hematological malignancies as well as limited types of solid tumors, have been ameliorated to a great ...
Linqin Wang +5 more
openaire +2 more sources